🚀 VC round data is live in beta, check it out!
Monte Rosa Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Monte Rosa Therapeutics and similar public comparables like Generate Biomedicines, Ardelyx, Iovance Biotherapeutics, HBM Holdings and more.
Monte Rosa Therapeutics Overview
About Monte Rosa Therapeutics
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
Founded
2019
HQ
Employees
134
Website
Financials (LTM)
EV
$1B
Monte Rosa Therapeutics Financials
Monte Rosa Therapeutics reported last 12-month revenue of $101M and negative EBITDA of ($45M).
In the same LTM period, Monte Rosa Therapeutics generated $101M in gross profit, ($45M) in EBITDA losses, and had net loss of ($75M).
Revenue (LTM)
Monte Rosa Therapeutics P&L
In the most recent fiscal year, Monte Rosa Therapeutics reported revenue of $124M and EBITDA of ($46M).
Monte Rosa Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $101M | XXX | $124M | XXX | XXX | XXX |
| Gross Profit | $101M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($45M) | XXX | ($46M) | XXX | XXX | XXX |
| EBITDA Margin | (44%) | XXX | (37%) | XXX | XXX | XXX |
| EBIT Margin | (90%) | XXX | (44%) | XXX | XXX | XXX |
| Net Profit | ($75M) | XXX | ($39M) | XXX | XXX | XXX |
| Net Margin | (74%) | XXX | (31%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Monte Rosa Therapeutics Stock Performance
Monte Rosa Therapeutics has current market cap of $2B, and enterprise value of $1B.
Market Cap Evolution
Monte Rosa Therapeutics' stock price is $19.78.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $2B | 0.0% | XXX | XXX | XXX | $-0.48 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMonte Rosa Therapeutics Valuation Multiples
Monte Rosa Therapeutics trades at 12.3x EV/Revenue multiple, and (27.7x) EV/EBITDA.
EV / Revenue (LTM)
Monte Rosa Therapeutics Financial Valuation Multiples
As of April 20, 2026, Monte Rosa Therapeutics has market cap of $2B and EV of $1B.
Equity research analysts estimate Monte Rosa Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Monte Rosa Therapeutics has a P/E ratio of (21.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 12.3x | XXX | 10.1x | XXX | XXX | XXX |
| EV/EBITDA | (27.7x) | XXX | (27.2x) | XXX | XXX | XXX |
| EV/EBIT | (13.7x) | XXX | (23.0x) | XXX | XXX | XXX |
| EV/Gross Profit | 12.3x | XXX | — | XXX | XXX | XXX |
| P/E | (21.2x) | XXX | (41.0x) | XXX | XXX | XXX |
| EV/FCF | (52.8x) | XXX | (45.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Monte Rosa Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Monte Rosa Therapeutics Margins & Growth Rates
Monte Rosa Therapeutics' revenue in the last 12 month declined by (47%).
Monte Rosa Therapeutics' revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $1.3M for the same period.
Monte Rosa Therapeutics' rule of 40 is (109%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Monte Rosa Therapeutics' rule of X is (201%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Monte Rosa Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (47%) | XXX | (61%) | XXX | XXX | XXX |
| EBITDA Margin | (44%) | XXX | (37%) | XXX | XXX | XXX |
| EBITDA Growth | (96%) | XXX | (49%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (109%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (201%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.3M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 39% | XXX | 29% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 153% | XXX | 114% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 144% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Monte Rosa Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Monte Rosa Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Generate Biomedicines | XXX | XXX | XXX | XXX | XXX | XXX |
| Ardelyx | XXX | XXX | XXX | XXX | XXX | XXX |
| Iovance Biotherapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| HBM Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| Bicara Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Monte Rosa Therapeutics M&A Activity
Monte Rosa Therapeutics acquired XXX companies to date.
Last acquisition by Monte Rosa Therapeutics was on XXXXXXXX, XXXXX. Monte Rosa Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Monte Rosa Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMonte Rosa Therapeutics Investment Activity
Monte Rosa Therapeutics invested in XXX companies to date.
Monte Rosa Therapeutics made its latest investment on XXXXXXXX, XXXXX. Monte Rosa Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Monte Rosa Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Monte Rosa Therapeutics
| When was Monte Rosa Therapeutics founded? | Monte Rosa Therapeutics was founded in 2019. |
| Where is Monte Rosa Therapeutics headquartered? | Monte Rosa Therapeutics is headquartered in United States. |
| How many employees does Monte Rosa Therapeutics have? | As of today, Monte Rosa Therapeutics has over 134 employees. |
| Who is the CEO of Monte Rosa Therapeutics? | Monte Rosa Therapeutics' CEO is Markus Warmuth. |
| Is Monte Rosa Therapeutics publicly listed? | Yes, Monte Rosa Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Monte Rosa Therapeutics? | Monte Rosa Therapeutics trades under GLUE ticker. |
| When did Monte Rosa Therapeutics go public? | Monte Rosa Therapeutics went public in 2021. |
| Who are competitors of Monte Rosa Therapeutics? | Monte Rosa Therapeutics main competitors are Generate Biomedicines, Ardelyx, Iovance Biotherapeutics, HBM Holdings. |
| What is the current market cap of Monte Rosa Therapeutics? | Monte Rosa Therapeutics' current market cap is $2B. |
| What is the current revenue of Monte Rosa Therapeutics? | Monte Rosa Therapeutics' last 12 months revenue is $101M. |
| What is the current revenue growth of Monte Rosa Therapeutics? | Monte Rosa Therapeutics revenue growth (NTM/LTM) is (47%). |
| What is the current EV/Revenue multiple of Monte Rosa Therapeutics? | Current revenue multiple of Monte Rosa Therapeutics is 12.3x. |
| Is Monte Rosa Therapeutics profitable? | No, Monte Rosa Therapeutics is not profitable. |
| What is the current EBITDA of Monte Rosa Therapeutics? | Monte Rosa Therapeutics has negative EBITDA and is not profitable. |
| What is Monte Rosa Therapeutics' EBITDA margin? | Monte Rosa Therapeutics' last 12 months EBITDA margin is (44%). |
| What is the current EV/EBITDA multiple of Monte Rosa Therapeutics? | Current EBITDA multiple of Monte Rosa Therapeutics is (27.7x). |
| What is the current FCF of Monte Rosa Therapeutics? | Monte Rosa Therapeutics' last 12 months FCF is ($24M). |
| What is Monte Rosa Therapeutics' FCF margin? | Monte Rosa Therapeutics' last 12 months FCF margin is (23%). |
| What is the current EV/FCF multiple of Monte Rosa Therapeutics? | Current FCF multiple of Monte Rosa Therapeutics is (52.8x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.